Last edition
News about "Pozdeutinurad"
Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.
Pozdeutinurad | 11/02/2026 | By News Bureau
Viva Biotech-Backed Arthrosi Enters USD 1.5 Billion Acquisition Deal with Sobi
Biovitrum AB (Sobi) has entered into an acquisition agreement with Viva Biotech–backed Arthrosi Therapeutics, with a total deal value of up to USD 1.5 billion, including USD 950 million upfront and up to USD 550 million in contingent payments, subject to closing in the first half of 2026.
Pozdeutinurad | 16/12/2025 | By News Bureau | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy